ArticleNature communications2023
Next generation pan-cancer blood proteome profiling using proximity extension assay.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Development and Validation of a Streamlined Workflow for Proteomic Analysis of Proteins and Post-translational Modifications from Dried Blood.Journal of proteome research · 2026Article
- Cross-Cancer Circulating Proteins for the Prognosis of Primary and Metastatic Liver Cancer Treated with Local Ablation: Post Hoc Exploratory Analysis of the ESTIMATE Trial.Radiology. Imaging cancer · 2026Article
- Plasma proteome-metabolome signatures enable non-invasive early detection and lymph node risk stratification in breast cancer.Molecular cancer · 2026Article
- Longitudinal protein profiling of blood during childhood into early adulthood.Nature communications · 2026Article
- New opportunities and challenges for nonshedder tumors.Fundamental research · 2026Review
- A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts.Clinical and experimental medicine · 2026Article
- Article
- Mass Spectrometry Proteomics: A Key to Faster Drug Discovery.Journal of medicinal chemistry · 2026Review
- HDAnalyzeR: streamlining data analysis for biomarker research.Bioinformatics advances · 2026Article
- Systemic sclerosis-associated pulmonary arterial hypertension and pulmonary fibrosis: exploring biomarker discriminators with advanced omics in a Caucasian cohort.Frontiers in immunology · 2026Article
- Plasma protein profiling predicts cancer in patients with non-specific symptoms.Nature communications · 2025Article
- Article
- Article
- Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes.Nature communications · 2025Article
- Development and validation of a streamlined workflow for proteomic analysis of proteins and post-translational modifications from dried blood.bioRxiv : the preprint server for biology · 2025Article
- Identification and verification of exosome-related gene signature to predict the cancer status and prognosis of prostate cancer.Discover oncology · 2025Article
- Next-generation leukemia diagnostics: Integrating LC-MS/MS proteomics with liquid biopsy platforms.The journal of liquid biopsy · 2025Review
- Plasma proteomic signature for preoperative prediction of microvascular invasion in HCC.JHEP reports : innovation in hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive characterization of blood proteome profiles in cancer patients can contribute to a better understanding of the disease etiology, resulting in earlier diagnosis, risk stratification and better monitoring of the different cancer subtypes. Here, we describe the use of next generation protein profiling to explore the proteome signature in blood across patients representing many of the major cancer types. Plasma profiles of 1463 proteins from more than 1400 cancer patients are measured in minute amounts of blood collected at the time of diagnosis and before treatment. An open access Disease Blood Atlas resource allows the exploration of the individual protein profiles in blood collected from the individual cancer patients. We also present studies in which classification models based on machine learning have been used for the identification of a set of proteins associated with each of the analyzed cancers. The implication for cancer precision medicine of next generation plasma profiling is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.